{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:36:13Z","timestamp":1789763773774,"version":"4.0.1"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170096"],"award-info":[{"award-number":["82170096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["2022105330305"],"award-info":[{"award-number":["2022105330305"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.lfs.2023.122121","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T16:42:13Z","timestamp":1695400933000},"page":"122121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The role of vasoactive intestinal peptide in pulmonary diseases"],"prefix":"10.1016","volume":"332","author":[{"given":"Hong-Lin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cha-Xiang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10204","key":"10.1016\/j.lfs.2023.122121_bb0005","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0010","doi-asserted-by":"crossref","first-page":"105951","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","volume":"55","author":"Li","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MED.0000000000000218","article-title":"Vasoactive intestinal peptide\/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer","volume":"23","author":"Moody","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.peptides.2009.12.014","article-title":"Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients","volume":"31","author":"Burian","year":"2010","journal-title":"Peptides"},{"issue":"4007","key":"10.1016\/j.lfs.2023.122121_bb0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/science.174.4007.422","article-title":"Intestinal secretion: stimulation by peptides","volume":"174","author":"Barbezat","year":"1971","journal-title":"Science"},{"issue":"4\u20136","key":"10.1016\/j.lfs.2023.122121_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00210-007-0232-0","article-title":"Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications","volume":"377","author":"Onoue","year":"2008","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1465-9921-12-45","article-title":"Prospect of vasoactive intestinal peptide therapy for COPD\/PAH and asthma: a review","volume":"12","author":"Wu","year":"2011","journal-title":"Respir. Res."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.122121_bb0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2005.12.055","article-title":"Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors","volume":"533","author":"Groneberg","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0045","first-page":"1732","article-title":"Vasoactive intestinal peptide receptor scintigraphy","volume":"36","author":"Virgolini","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lfs.2023.122121_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fendo.2018.00345","article-title":"Neuropeptide G protein-coupled receptors as oncotargets","volume":"9","author":"Moody","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0055","doi-asserted-by":"crossref","first-page":"17152","DOI":"10.1038\/s41598-019-53676-3","article-title":"Vasoactive intestinal peptide induces glucose and neutral amino acid uptake through mTOR signalling in human cytotrophoblast cells","volume":"9","author":"Merech","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.yexcr.2018.01.042","article-title":"Vasoactive intestinal peptide inhibits airway smooth muscle cell proliferation in a mouse model of asthma via the ERK1\/2 signaling pathway","volume":"364","author":"Wang","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0065","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0006-291X(02)00283-8","article-title":"Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1\/MEK4\/JNK signaling pathway in endotoxin-activated microglia","volume":"293","author":"Delgado","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/scd.2019.0148","article-title":"Vasoactive intestinal peptide stimulates bone marrow-mesenchymal stem cells osteogenesis differentiation by activating Wnt\/\u03b2-catenin signaling pathway and promotes rat skull defect repair","volume":"29","author":"Shi","year":"2020","journal-title":"Stem Cells Dev."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0075","first-page":"L749","article-title":"Regulation of apoptosis by vasoactive peptides","volume":"281","author":"Filippatos","year":"2001","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.lfs.2023.122121_bb0080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1196\/annals.1418.014","article-title":"The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation","volume":"1144","author":"Said","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122121_bb0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1749-6632.2000.tb06954.x","article-title":"Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP","volume":"921","author":"Leceta","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122121_bb0090","doi-asserted-by":"crossref","first-page":"109596","DOI":"10.1016\/j.biopha.2019.109596","article-title":"Vasoactive intestinal peptide suppresses the NLRP3 inflammasome activation in lipopolysaccharide-induced acute lung injury mice and macrophages","volume":"121","author":"Zhou","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"47","key":"10.1016\/j.lfs.2023.122121_bb0095","doi-asserted-by":"crossref","first-page":"31427","DOI":"10.1074\/jbc.273.47.31427","article-title":"Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein\/c-Jun","volume":"273","author":"Delgado","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0100","first-page":"L880","article-title":"Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP","volume":"291","author":"Szema","year":"2006","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"3\u20134","key":"10.1016\/j.lfs.2023.122121_bb0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejps.2010.08.007","article-title":"Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats","volume":"41","author":"Onoue","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2023.122121_bb0110","first-page":"304","article-title":"Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma","volume":"97","author":"Saga","year":"1984","journal-title":"Trans. Assoc. Am. Phys."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0115","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1152\/jappl.1986.61.4.1322","article-title":"VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways","volume":"61","author":"Palmer","year":"1986","journal-title":"J. Appl. Physiol. (1985)"},{"issue":"3","key":"10.1016\/j.lfs.2023.122121_bb0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/thorax.58.3.217","article-title":"Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma","volume":"58","author":"Lind\u00e9n","year":"2003","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0125","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1476-5381.2010.00975.x","article-title":"Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors","volume":"161","author":"Tannu","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"3951","key":"10.1016\/j.lfs.2023.122121_bb0130","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","article-title":"Polypeptide with broad biological activity: isolation from small intestine","volume":"169","author":"Said","year":"1970","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1476-5381.1984.tb10766.x","article-title":"Relaxation of cat tracheobronchial and pulmonary arterial smooth muscle by vasoactive intestinal peptide: lack of influence by peptidase inhibitors","volume":"82","author":"Altiere","year":"1984","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0140","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0196-9781(93)90109-T","article-title":"Comparative study of vascular relaxation and receptor binding by PACAP and VIP","volume":"14","author":"Huang","year":"1993","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00210505","article-title":"Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects","volume":"220","author":"Dey","year":"1981","journal-title":"Cell Tissue Res."},{"issue":"3","key":"10.1016\/j.lfs.2023.122121_bb0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.resp.2007.06.017","article-title":"Fluid secretion by submucosal glands of the tracheobronchial airways","volume":"159","author":"Ballard","year":"2007","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/labinvest.3780283","article-title":"Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways","volume":"81","author":"Groneberg","year":"2001","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0160","first-page":"L83","article-title":"Mucociliary clearance and submucosal gland secretion in the ex vivo ferret trachea","volume":"307","author":"Jeong","year":"2014","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.lfs.2023.122121_bb0165","first-page":"55(4)","article-title":"Neuropeptide regulation of secretion and inflammation in human airway gland serous cells","author":"McMahon","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apha.12427","article-title":"The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases","volume":"213","author":"Ganea","year":"2015","journal-title":"Acta Physiol (Oxford)"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0175","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.4049\/jimmunol.172.12.7289","article-title":"c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide","volume":"172","author":"Voice","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122121_bb0180","doi-asserted-by":"crossref","first-page":"723173","DOI":"10.3389\/fimmu.2021.723173","article-title":"The role of vasoactive intestinal peptide and mast cells in the regulatory effect of Lactobacillus casei ATCC 393 on intestinal mucosal immune barrier","volume":"12","author":"Song","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.lfs.2023.122121_bb0185","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/bph.14609","article-title":"Vasoactive intestinal peptide shapes first-trimester placenta trophoblast, vascular, and immune cell cooperation","volume":"176","author":"Paparini","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02410-22","article-title":"C-fiber degeneration enhances alveolar macrophage-mediated IFN-\u03b1\/\u03b2 response to respiratory syncytial virus","volume":"10","author":"He","year":"2022","journal-title":"Microbiol Spectr."},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0195","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0092-8674(00)81005-3","article-title":"A license to kill","volume":"85","author":"Fraser","year":"1996","journal-title":"Cell"},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.122121_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-0115(00)00174-9","article-title":"Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide","volume":"93","author":"Said","year":"2000","journal-title":"Regul. Pept."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.peptides.2010.10.021","article-title":"Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis","volume":"32","author":"Misaka","year":"2011","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0210","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2174\/138161207780619000","article-title":"Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer","volume":"13","author":"Moody","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2023.122121_bb0215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2172-12-66","article-title":"Vasoactive Intestinal Peptide Knockout (VIP KO) mouse model of sulfite-sensitive asthma: up-regulation of novel lung carbonyl reductase","volume":"12","author":"Szema","year":"2011","journal-title":"BMC Immunol."},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0220","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.peptides.2010.07.017","article-title":"Vasoactive intestinal peptide induces surfactant protein A expression in ATII cells through activation of PKC\/c-Fos pathway","volume":"31","author":"Li","year":"2010","journal-title":"Peptides"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0225","first-page":"1652","article-title":"Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants","volume":"25","author":"Li","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.122121_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.regpep.2008.12.003","article-title":"Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells","volume":"153","author":"Guan","year":"2009","journal-title":"Regul. Pept."},{"issue":"9","key":"10.1016\/j.lfs.2023.122121_bb0235","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.peptides.2007.07.027","article-title":"Intracellular signaling molecules involved in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells","volume":"28","author":"Guan","year":"2007","journal-title":"Peptides"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0240","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.peptides.2006.08.004","article-title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","volume":"27","author":"Guan","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2023.122121_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-3-030-63046-1_19","article-title":"Inflammation in pulmonary arterial hypertension","volume":"1303","author":"Klouda","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"14","key":"10.1016\/j.lfs.2023.122121_bb0250","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.lfs.2023.122121_bb0255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.01.17100010","article-title":"Do we need controlled clinical trials in pulmonary arterial hypertension?","volume":"17","author":"Gali\u00e8","year":"2001","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2008.10.002","article-title":"Therapeutic targets in pulmonary arterial hypertension","volume":"121","author":"Rhodes","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0270","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201501-0196OC","article-title":"Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension","volume":"192","author":"Benza","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2023.122121_bb0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reprotox.2015.06.048","article-title":"Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension","volume":"56","author":"de Raaf","year":"2015","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"17","key":"10.1016\/j.lfs.2023.122121_bb0285","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/CIRCULATIONAHA.106.676809","article-title":"Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy","volume":"115","author":"Schermuly","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1465-9921-12-141","article-title":"VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension","volume":"12","author":"Hamidi","year":"2011","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0295","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","article-title":"Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene","volume":"115","author":"Said","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1465-9921-12-58","article-title":"Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension","volume":"12","author":"Habre","year":"2011","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0305","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1203\/PDR.0b013e3181b33804","article-title":"Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets","volume":"66","author":"Vuckovic","year":"2009","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1152\/japplphysiol.00861.2013","article-title":"Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats","volume":"117","author":"Koga","year":"2014","journal-title":"J. Appl. Physiol. (1985)"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0315","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.peptides.2009.08.010","article-title":"Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation","volume":"30","author":"St Hilaire","year":"2009","journal-title":"Peptides"},{"issue":"8","key":"10.1016\/j.lfs.2023.122121_bb0320","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.peptides.2010.04.024","article-title":"Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation","volume":"31","author":"St Hilaire","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2023.122121_bb0325","doi-asserted-by":"crossref","first-page":"107576","DOI":"10.1016\/j.pharmthera.2020.107576","article-title":"Pulmonary arterial hypertension specific therapy: the old and the new","volume":"214","author":"Zolty","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","article-title":"Inhalation of vasoactive intestinal peptide in pulmonary hypertension","volume":"32","author":"Leuchte","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.lfs.2023.122121_bb0335","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0340","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.ejhg.5201711","article-title":"Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension","volume":"15","author":"Haberl","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"issue":"Suppl. 10","key":"10.1016\/j.lfs.2023.122121_bb0345","first-page":"173","article-title":"Aqueous extracts of cigarette tar containing the tar free radical cause DNA nicks in mammalian cells","volume":"102 Suppl 10","author":"Stone","year":"1994","journal-title":"Environ. Health Perspect."},{"issue":"9","key":"10.1016\/j.lfs.2023.122121_bb0350","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.peptides.2007.04.009","article-title":"Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma\/COPD","volume":"28","author":"Onoue","year":"2007","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0355","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/fcp.12811","article-title":"Immunomodulatory effect of N-acetyl-seryl-aspartyl-proline and vasoactive intestinal peptide on chronic obstructive pulmonary disease pathophysiology","volume":"36","author":"Cai","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0360","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.peptides.2009.09.032","article-title":"Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats","volume":"31","author":"Misaka","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2023.122121_bb0365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2017.09.002","article-title":"Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases","volume":"38","author":"Verma","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0370","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000439228","article-title":"Vasoactive intestinal peptide for diagnosing exacerbation in chronic obstructive pulmonary disease","volume":"90","author":"Mandal","year":"2015","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0375","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1183\/09031936.04.10031504","article-title":"Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis","volume":"24","author":"Miotto","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0380","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s002100100458","article-title":"The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery","volume":"364","author":"Schmidt","year":"2001","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170606","article-title":"NFATc3 and VIP in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease","volume":"12","author":"Szema","year":"2017","journal-title":"PLoS One"},{"issue":"10122","key":"10.1016\/j.lfs.2023.122121_bb0390","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0395","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1183\/09031936.00097109","article-title":"Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?","volume":"35","author":"Said","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2023.122121_bb0400","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ejphar.2016.10.014","article-title":"Conjugated alpha-alumina nanoparticle with vasoactive intestinal peptide as a nano-drug in treatment of allergic asthma in mice","volume":"791","author":"Athari","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.peptides.2010.09.022","article-title":"The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice","volume":"32","author":"Samarasinghe","year":"2011","journal-title":"Peptides"},{"issue":"19","key":"10.1016\/j.lfs.2023.122121_bb0410","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1056\/NEJM198905113201909","article-title":"Vasoactive intestinal polypeptide and asthma","volume":"320","author":"Said","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2023.122121_bb0415","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0196-9781(86)90202-0","article-title":"Vasoactive intestinal peptide as a bronchodilator in severe asthma","volume":"7","author":"Morice","year":"1986","journal-title":"Peptides"},{"issue":"8361","key":"10.1016\/j.lfs.2023.122121_bb0420","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(83)91272-2","article-title":"Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects","volume":"2","author":"Morice","year":"1983","journal-title":"Lancet"},{"issue":"8374","key":"10.1016\/j.lfs.2023.122121_bb0425","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(84)91795-1","article-title":"VIP as bronchodilator","volume":"1","author":"Morice","year":"1984","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0430","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2021.23280","article-title":"What is cystic fibrosis?","volume":"327","author":"Endres","year":"2022","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0440","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis. What have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10290","key":"10.1016\/j.lfs.2023.122121_bb0445","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"52","key":"10.1016\/j.lfs.2023.122121_bb0450","doi-asserted-by":"crossref","first-page":"50710","DOI":"10.1074\/jbc.M208826200","article-title":"Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands","volume":"277","author":"Joo","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0455","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcf.2020.06.013","article-title":"Disrupted local innervation results in less VIP expression in CF mice tissues","volume":"20","author":"Semaniakou","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0460","first-page":"C53","article-title":"VIP-dependent increase in F508del-CFTR membrane localization is mediated by PKC\u03b5","volume":"301","author":"Alcolado","year":"2011","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0465","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1085\/jgp.201812143","article-title":"Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains","volume":"151","author":"Abu-Arish","year":"2019","journal-title":"J. Gen. Physiol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0470","first-page":"C195","article-title":"Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice","volume":"307","author":"Alcolado","year":"2014","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0475","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1172\/JCI31992","article-title":"Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis","volume":"117","author":"Choi","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2023.122121_bb0480","doi-asserted-by":"crossref","first-page":"105224","DOI":"10.1016\/j.phrs.2020.105224","article-title":"Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms","volume":"163","author":"He","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2023.122121_bb0485","doi-asserted-by":"crossref","first-page":"20156","DOI":"10.1038\/srep20156","article-title":"Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0490","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/iep.12130","article-title":"Vasoactive intestinal peptide suppresses macrophage-mediated inflammation by downregulating interleukin-17A expression via PKA- and PKC-dependent pathways","volume":"96","author":"Ran","year":"2015","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.lfs.2023.122121_bb0495","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2018.03.002","article-title":"Vasoactive intestinal peptide overexpression mediated by lentivirus attenuates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation","volume":"97","author":"Sun","year":"2018","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0500","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.regpep.2010.11.008","article-title":"Vasoactive intestinal peptide re-balances TREM-1\/TREM-2 ratio in acute lung injury","volume":"167","author":"Sun","year":"2011","journal-title":"Regul. Pept."},{"issue":"7","key":"10.1016\/j.lfs.2023.122121_bb0505","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cbin.11151","article-title":"Vasoactive intestinal peptide inhibits the activation of murine fibroblasts and expression of interleukin 17 receptor C","volume":"43","author":"Zhang","year":"2019","journal-title":"Cell Biol. Int."},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0510","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1210\/en.2011-1631","article-title":"17\u03b2-estradiol protects the lung against acute injury: possible mediation by vasoactive intestinal polypeptide","volume":"152","author":"Hamidi","year":"2011","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0515","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.4049\/jimmunol.1400368","article-title":"Critical role for the NLRP3 inflammasome during acute lung injury","volume":"192","author":"Grailer","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0520","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/JLB.5COVA1121-626R","article-title":"VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells","volume":"111","author":"Temerozo","year":"2022","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0525","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1007\/s11356-021-17824-5","article-title":"Anticipated pharmacological role of Aviptadil on COVID-19","volume":"29","author":"Mukherjee","year":"2022","journal-title":"Environ. Sci. Pollut. Res. Int."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0530","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s13063-022-06723-w","article-title":"Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial","volume":"23","author":"Boesing","year":"2022","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0535","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/CCM.0000000000005660","article-title":"The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial","volume":"50","author":"Youssef","year":"2022","journal-title":"Crit. Care Med."},{"issue":"10082","key":"10.1016\/j.lfs.2023.122121_bb0540","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0545","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","article-title":"Idiopathic pulmonary fibrosis: pathogenesis and management","volume":"19","author":"Sgalla","year":"2018","journal-title":"Respir. Res."},{"issue":"Pt B","key":"10.1016\/j.lfs.2023.122121_bb0550","article-title":"Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: restoring autophagy in alveolar epithelial cells","volume":"101","author":"Duan","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"10299","key":"10.1016\/j.lfs.2023.122121_bb0555","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.lfs.2023.122121_bb0560","doi-asserted-by":"crossref","first-page":"14373","DOI":"10.1073\/pnas.95.24.14373","article-title":"Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo","volume":"95","author":"Maruno","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2\u20133","key":"10.1016\/j.lfs.2023.122121_bb0565","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0169-5002(00)00168-9","article-title":"Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells","volume":"31","author":"Casibang","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2023.122121_bb0570","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2000.tb06947.x","article-title":"VPAC1 receptors and lung cancer","volume":"921","author":"Moody","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122121_bb0575","doi-asserted-by":"crossref","first-page":"170672","DOI":"10.1016\/j.peptides.2021.170672","article-title":"Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma","volume":"146","author":"D\u2019Amico","year":"2021","journal-title":"Peptides"},{"issue":"8","key":"10.1016\/j.lfs.2023.122121_bb0580","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/1097-0142(20011015)92:8<2172::AID-CNCR1560>3.0.CO;2-4","article-title":"A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines","volume":"92","author":"Gelber","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0585","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"26","key":"10.1016\/j.lfs.2023.122121_bb0590","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1056\/NEJMc2000343","article-title":"Vasoactive intestinal peptide in checkpoint inhibitor-induced pneumonitis","volume":"382","author":"Frye","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122121_bb0595","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.peptides.2015.03.018","article-title":"Neuropeptides as lung cancer growth factors","volume":"72","author":"Moody","year":"2015","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0600","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1073\/pnas.90.10.4345","article-title":"A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth","volume":"90","author":"Moody","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.lfs.2023.122121_bb0605","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM199410273311703","article-title":"Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors","volume":"331","author":"Virgolini","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0610","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gut.19.11.1049","article-title":"Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects","volume":"19","author":"Domschke","year":"1978","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.lfs.2023.122121_bb0615","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/00365527809182195","article-title":"Radioimmunoassay of vasoactive intestinal polypeptide in plasma","volume":"13","author":"Burhol","year":"1978","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0620","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(00)00229-7","article-title":"Vasoactive intestinal peptide: cardiovascular effects","volume":"49","author":"Henning","year":"2001","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.lfs.2023.122121_bb0625","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/17425247.2.6.965","article-title":"Paediatric pulmonary drug delivery: considerations in asthma treatment","volume":"2","author":"Berger","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0630","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lfs.2005.12.049","article-title":"Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration","volume":"79","author":"Ohmori","year":"2006","journal-title":"Life Sci."},{"issue":"31","key":"10.1016\/j.lfs.2023.122121_bb0635","doi-asserted-by":"crossref","first-page":"24003","DOI":"10.1074\/jbc.M002325200","article-title":"Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide","volume":"275","author":"Nicole","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0640","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(98)00662-1","article-title":"Influence of selective VIP receptor agonists in the rat gastric fundus","volume":"359","author":"Robberecht","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0645","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0196-9781(97)00228-3","article-title":"Development of high affinity selective VIP1 receptor agonists","volume":"18","author":"Gourlet","year":"1997","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.lfs.2023.122121_bb0650","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0196-9781(01)00436-3","article-title":"GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity","volume":"22","author":"Ito","year":"2001","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0655","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0026-895X(24)12476-5","article-title":"Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template","volume":"58","author":"Tams","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0660","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1124\/jpet.105.088823","article-title":"Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide\/pituitary adenylate cyclase-activating polypeptide receptors","volume":"315","author":"Igarashi","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0665","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-2999(98)00133-2","article-title":"Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes","volume":"348","author":"Gourlet","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0670","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0196-9781(97)00230-1","article-title":"In vitro properties of a high affinity selective antagonist of the VIP1 receptor","volume":"18","author":"Gourlet","year":"1997","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0675","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bip.360370203","article-title":"Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma","volume":"37","author":"Bolin","year":"1995","journal-title":"Biopolymers"},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0680","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-3565(24)36654-6","article-title":"Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor","volume":"281","author":"Xia","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5 Pt 2","key":"10.1016\/j.lfs.2023.122121_bb0685","first-page":"H1648","article-title":"The stable VIP analogue, Ro 24-9981, potentiates bradykinin-induced increases in clearance of macromolecules","volume":"269","author":"Gao","year":"1995","journal-title":"Am. J. Phys."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0690","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1124\/jpet.106.112276","article-title":"Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo","volume":"320","author":"Pan","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"50","key":"10.1016\/j.lfs.2023.122121_bb0695","doi-asserted-by":"crossref","first-page":"16463","DOI":"10.1523\/JNEUROSCI.2131-15.2015","article-title":"Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice","volume":"35","author":"Olson","year":"2015","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.lfs.2023.122121_bb0700","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0196-9781(00)00309-0","article-title":"Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor","volume":"21","author":"Moreno","year":"2000","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.lfs.2023.122121_bb0705","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.bbrc.2018.07.144","article-title":"Discovery of artificial VIPR2-antagonist peptides possessing receptor- and ligand-selectivity","volume":"503","author":"Sakamoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0710","first-page":"161","article-title":"Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors","volume":"273","author":"Gozes","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.122121_bb0715","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.regpep.2004.04.025","article-title":"Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke","volume":"123","author":"Onoue","year":"2004","journal-title":"Regul. Pept."},{"issue":"12","key":"10.1016\/j.lfs.2023.122121_bb0720","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.lfs.2003.07.048","article-title":"Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine","volume":"74","author":"Onoue","year":"2004","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0725","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1386207317666141128104031","article-title":"In silico classification and prediction of VIP derivatives as VPAC1\/VPAC2 receptor agonists\/antagonists","volume":"18","author":"Li","year":"2015","journal-title":"Comb. Chem. High Throughput Screen."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0730","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/mi.2016.51","article-title":"Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47(phox) phosphorylation pathway in monocytes","volume":"10","author":"Chedid","year":"2017","journal-title":"Mucosal Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0735","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/87859","article-title":"VIP: a very important protein in arthritis","volume":"7","author":"Firestein","year":"2001","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0740","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2003.50141","article-title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn\u2019s disease","volume":"124","author":"Abad","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.lfs.2023.122121_bb0745","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2353\/ajpath.2006.051081","article-title":"Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses","volume":"168","author":"Gonzalez-Rey","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122121_bb0750","first-page":"62","article-title":"VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production","volume":"30","author":"Kojima","year":"2005","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.lfs.2023.122121_bb0755","first-page":"1282","article-title":"Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: in vitro and in vivo bronchodilator studies","volume":"270","author":"O\u2019Donnell","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.lfs.2023.122121_bb0760","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/jir.1995.15.993","article-title":"Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553","volume":"15","author":"Tang","year":"1995","journal-title":"J. Interf. Cytokine Res."},{"issue":"5","key":"10.1016\/j.lfs.2023.122121_bb0765","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/diabetes.51.5.1453","article-title":"A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes","volume":"51","author":"Tsutsumi","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2023.122121_bb0770","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-1172-9-4","article-title":"VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models","volume":"9","author":"Hadwen","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.lfs.2023.122121_bb0775","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.npep.2012.08.008","article-title":"The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats","volume":"47","author":"Darsalia","year":"2013","journal-title":"Neuropeptides"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523007567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523007567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:59:14Z","timestamp":1736333954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523007567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":155,"alternative-id":["S0024320523007567"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122121","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of vasoactive intestinal peptide in pulmonary diseases","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122121"}}